Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Cases and evidence for panel testing in cancer genetics: Is site-specific testing dead?

Thomas MH, Higgs LK, Modesitt SC, Schroen AT, Ring KL, Dillon PM.

J Genet Couns. 2019 Jun;28(3):700-707. doi: 10.1002/jgc4.1044. Epub 2019 Feb 1.

PMID:
30706980
2.

IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1.

Dill EA, Dillon PM, Bullock TN, Mills AM.

Mod Pathol. 2018 Oct;31(10):1513-1522. doi: 10.1038/s41379-018-0061-3. Epub 2018 May 25.

PMID:
29802358
3.

CONCORD biomarker prediction for novel drug introduction to different cancer types.

Kim Y, Dillon PM, Park T, Lee JK.

Oncotarget. 2017 Dec 9;9(1):1091-1106. doi: 10.18632/oncotarget.23124. eCollection 2018 Jan 2.

4.

Alcohol Use and Problems in Daily and Non-Daily Coffee Drinking College Females.

Kelpin SS, Moore TB, Hull LC, Dillon PM, Perry BL, Thacker LR, Hancock L, Svikis DS.

J Subst Use. 2018;23(6):574-578. doi: 10.1080/14659891.2018.1459901. Epub 2018 Apr 9.

5.

A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.

Dillon PM, Petroni GR, Smolkin ME, Brenin DR, Chianese-Bullock KA, Smith KT, Olson WC, Fanous IS, Nail CJ, Brenin CM, Hall EH, Slingluff CL Jr.

J Immunother Cancer. 2017 Nov 21;5(1):92. doi: 10.1186/s40425-017-0295-5.

6.

The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma.

Mills AM, Dill EA, Moskaluk CA, Dziegielewski J, Bullock TN, Dillon PM.

Am J Surg Pathol. 2018 Feb;42(2):183-191. doi: 10.1097/PAS.0000000000000949.

PMID:
28914717
7.

Association of Incident Amelanotic Melanoma With Phenotypic Characteristics, MC1R Status, and Prior Amelanotic Melanoma.

Vernali S, Waxweiler WT, Dillon PM, Kanetsky PA, Orlow I, Luo L, Busam KJ, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, Gallagher RP, Zanetti R, Rosso S, Sacchetto L, Dwyer T, Cust AE, Ollila DW, Begg CB, Berwick M, Thomas NE; GEM Study Group.

JAMA Dermatol. 2017 Oct 1;153(10):1026-1031. doi: 10.1001/jamadermatol.2017.2444.

8.

Anti-Yo Mediated Paraneoplastic Cerebellar Degeneration Associated with Pseudobulbar Affect in a Patient with Breast Cancer.

Martin AN, Dillon PM, Jones DE, Brenin DR, Lapides DA.

Case Rep Oncol Med. 2017;2017:8120689. doi: 10.1155/2017/8120689. Epub 2017 Mar 9.

9.

A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma.

Dillon PM, Petroni GR, Horton BJ, Moskaluk CA, Fracasso PM, Douvas MG, Varhegyi N, Zaja-Milatovic S, Thomas CY.

Clin Cancer Res. 2017 Aug 1;23(15):4138-4145. doi: 10.1158/1078-0432.CCR-16-2942. Epub 2017 Apr 4.

10.

A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.

Jovanović B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA.

Clin Cancer Res. 2017 Aug 1;23(15):4035-4045. doi: 10.1158/1078-0432.CCR-16-3055. Epub 2017 Mar 7.

11.

Early Palliative Care Reduces End-of-Life Intensive Care Unit (ICU) Use but Not ICU Course in Patients with Advanced Cancer.

Romano AM, Gade KE, Nielsen G, Havard R, Harrison JH Jr, Barclay J, Stukenborg GJ, Read PW, Blackhall LJ, Dillon PM.

Oncologist. 2017 Mar;22(3):318-323. doi: 10.1634/theoncologist.2016-0227. Epub 2017 Feb 20.

12.

PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors.

Dill EA, Gru AA, Atkins KA, Friedman LA, Moore ME, Bullock TN, Cross JV, Dillon PM, Mills AM.

Am J Surg Pathol. 2017 Mar;41(3):334-342. doi: 10.1097/PAS.0000000000000780.

PMID:
28195880
13.

Lobular Breast Cancer and Abdominal Metastases: A Retrospective Review and Impact on Survival.

Winn JS, Baker MG, Fanous IS, Slack-Davis JK, Atkins KA, Dillon PM.

Oncology. 2016;91(3):135-42. doi: 10.1159/000447264. Epub 2016 Jun 30.

PMID:
27355204
14.

Orbital Metastases from Breast Cancer: Retrospective Analysis at an Academic Cancer Center.

Pierson TM, Tebit EV, El Sayed A, Smolkin ME, Dillon PM.

Breast J. 2016 Jul;22(4):447-50. doi: 10.1111/tbj.12604. Epub 2016 May 3.

PMID:
27143519
15.

Longitudinal patterns of cancer patient reported outcomes in end of life care predict survival.

Stukenborg GJ, Blackhall LJ, Harrison JH, Dillon PM, Read PW.

Support Care Cancer. 2016 May;24(5):2217-2224. doi: 10.1007/s00520-015-3024-y. Epub 2015 Nov 16.

16.

Tubular carcinoma of the breast: institutional and SEER database analysis supporting a unique classification.

Romano AM, Wages NA, Smolkin M, Fortune KL, Atkins K, Dillon PM.

Breast Dis. 2015;35(2):103-11. doi: 10.3233/BD-140396.

PMID:
25567000
17.

Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials.

Dillon PM, Chakraborty S, Moskaluk CA, Joshi PJ, Thomas CY.

Head Neck. 2016 Apr;38(4):620-7. doi: 10.1002/hed.23925. Epub 2015 Jun 16. Review.

18.

Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study.

Thomas NE, Kricker A, Waxweiler WT, Dillon PM, Busman KJ, From L, Groben PA, Armstrong BK, Anton-Culver H, Gruber SB, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Venn A, Kanetsky PA, Orlow I, Paine S, Ollila DW, Reiner AS, Luo L, Hao H, Frank JS, Begg CB, Berwick M; Genes, Environment, and Melanoma (GEM) Study Group.

JAMA Dermatol. 2014 Dec;150(12):1306-314.

19.

A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes.

Dillon PM, Olson WC, Czarkowski A, Petroni GR, Smolkin M, Grosh WW, Chianese-Bullock KA, Deacon DH, Slingluff CL Jr.

J Immunother Cancer. 2014 Jul 15;2:23. doi: 10.1186/2051-1426-2-23. eCollection 2014.

20.

Taxane associated subacute cutaneous lupus erythematosus.

Marchetti MA, Noland MM, Dillon PM, Greer KE.

Dermatol Online J. 2013 Aug 15;19(8):19259.

21.

Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors.

Combest AJ, Roberts PJ, Dillon PM, Sandison K, Hanna SK, Ross C, Habibi S, Zamboni B, Müller M, Brunner M, Sharpless NE, Zamboni WC.

Oncologist. 2012;17(10):1303-16. doi: 10.1634/theoncologist.2012-0274. Epub 2012 Sep 19.

22.

A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model.

Pritchard JE, Dillon PM, Conaway MR, Silva CM, Parsons SJ.

Oncology. 2012;83(6):305-20. doi: 10.1159/000341394. Epub 2012 Sep 5.

23.

Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.

Roberts PJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, Whittle MC, Duncan JS, Johnson SM, Combest AJ, Jin J, Zamboni WC, Johnson GL, Perou CM, Sharpless NE.

Clin Cancer Res. 2012 Oct 1;18(19):5290-303. doi: 10.1158/1078-0432.CCR-12-0563. Epub 2012 Aug 7.

24.

Simulation as a means to foster collaborative interdisciplinary education.

Dillon PM, Noble KA, Kaplan L.

Nurs Educ Perspect. 2009 Mar-Apr;30(2):87-90.

PMID:
19476071
25.

Intraspecific interference among larvae in a semivoltine dragonfly population.

Crowley PH, Dillon PM, Johnson DM, Watson CN.

Oecologia. 1987 Feb;71(3):447-456. doi: 10.1007/BF00378720.

PMID:
28312994

Supplemental Content

Loading ...
Support Center